Roche Will Challenge Amgen In U.S. EPO Market; Oncology Business Growing

Roche expects to enter the U.S. EPO market with the continuous erythropoetin receptor activator R-744, Global Pharmaceuticals Head William Burns told securities analysts during a July 23 meeting in Zurich